CD4 and neoplasm: 4T1 tumors from FGFRi-treated mice had significantly increased CD8+ T cells (cluster 1) and CD4+ T cells (cluster 2), and decreased myeloid-derived suppressor cells (MDSC) (cluster 7), suggesting enhanced anti-tumor immunity (Figure 2J).